Kayyem Jon Faiz 4
4 · Inhibrx Biosciences, Inc. · Filed Jun 7, 2024
Insider Transaction Report
Form 4
Kayyem Jon Faiz
Director
Transactions
- Purchase
Common Stock
2024-06-05$17.23/sh+49,284$849,163→ 1,142,145 total(indirect: By Trust) - Purchase
Common Stock
2024-06-05$17.89/sh+8,265$147,861→ 1,150,410 total(indirect: By Trust)
Footnotes (2)
- [F1]The shares were purchased in multiple transactions at prices ranging from $16.81 to $17.805, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F2]The shares were purchased in multiple transactions at prices ranging from $17.81 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.